Möller Hans-Jürgen
Department of Psychiatry, Ludwig-Maximilians-University München, Munich, Germany.
Dialogues Clin Neurosci. 2011;13(2):199-207. doi: 10.31887/DCNS.2011.13.2/hmoeller.
In recent years, so-called "effectiveness studies," also called "real-world studies" or "pragmatic trials," have gained increasing importance in the context of evidence-based medicine. These studies follow less restrictive methodological standards than phase III studies in terms of patient selection, comedication, and other design issues, and their results should therefore be better generalizable than those of phase III trials. Effectiveness studies, like other types of phase IV studies, can therefore contribute to knowledge about medications and supply relevant information in addition to that gained from phase III trials. However, the less restrictive design and inherent methodological problems of phase IV studies have to be carefully considered. For example, the greater variance caused by the different kinds of confounders as well as problematic design issues, such as insensitive primary outcome criteria, unblinded treatment conditions, inclusion of chronic refractory patients, etc, can lead to wrong conclusions. Due to these methodological problems, effectiveness studies are on a principally lower level of evidence, adding only a complementary view to the results of phase III trials without falsifying their results.
近年来,所谓的“有效性研究”,也被称为“真实世界研究”或“实用试验”,在循证医学背景下变得越来越重要。这些研究在患者选择、合并用药及其他设计问题方面遵循的方法学标准比III期研究宽松,因此其结果应比III期试验的结果更具普遍性。与其他IV期研究类型一样,有效性研究有助于增进对药物的了解,并能提供除III期试验所获信息之外的相关信息。然而,必须认真考虑IV期研究设计宽松以及固有的方法学问题。例如,由各种混杂因素导致的更大变异性以及有问题的设计问题,如不敏感的主要结局标准、未设盲的治疗条件、纳入慢性难治性患者等,可能会导致错误结论。由于这些方法学问题,有效性研究在证据水平上原则上较低,只是对III期试验结果增加一种补充观点,而不会推翻其结果。